GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » Piotroski F-Score

BTTX (Better Therapeutics) Piotroski F-Score : 0 (As of Jul. 19, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Better Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Better Therapeutics's Piotroski F-Score or its related term are showing as below:


Better Therapeutics Piotroski F-Score Historical Data

The historical data trend for Better Therapeutics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Better Therapeutics Piotroski F-Score Chart

Better Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
N/A N/A N/A 3.00

Better Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 3.00 N/A 2.00 1.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Net Income was -8.765 + -9.357 + -7.589 + -5.862 = $-31.57 Mil.
Cash Flow from Operations was -6.337 + -8.716 + -5.087 + -5.943 = $-26.08 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Sep22)
to the end of this year (Sep23) was
(28.221 + 22.943 + 12.808 + 11.604 + 10.722) / 5 = $17.2596 Mil.
Total Assets at the begining of this year (Sep22) was $28.22 Mil.
Long-Term Debt & Capital Lease Obligation was $7.72 Mil.
Total Current Assets was $7.35 Mil.
Total Current Liabilities was $12.94 Mil.
Net Income was -13.894 + -9.662 + -9.928 + -11.405 = $-44.89 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Sep21)
to the end of last year (Sep22) was
(57.798 + 50.958 + 40.291 + 37.103 + 28.221) / 5 = $42.8742 Mil.
Total Assets at the begining of last year (Sep21) was $57.80 Mil.
Long-Term Debt & Capital Lease Obligation was $11.66 Mil.
Total Current Assets was $23.49 Mil.
Total Current Liabilities was $9.31 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Better Therapeutics's current Net Income (TTM) was -31.57. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Better Therapeutics's current Cash Flow from Operations (TTM) was -26.08. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep22)
=-31.573/28.221
=-1.1187768

ROA (Last Year)=Net Income/Total Assets (Sep21)
=-44.889/57.798
=-0.77665317

Better Therapeutics's return on assets of this year was -1.1187768. Better Therapeutics's return on assets of last year was -0.77665317. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Better Therapeutics's current Net Income (TTM) was -31.57. Better Therapeutics's current Cash Flow from Operations (TTM) was -26.08. ==> -26.08 > -31.57 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=7.721/17.2596
=0.44734525

Gearing (Last Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=11.657/42.8742
=0.27188846

Better Therapeutics's gearing of this year was 0.44734525. Better Therapeutics's gearing of last year was 0.27188846. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep23)=Total Current Assets/Total Current Liabilities
=7.345/12.938
=0.56770753

Current Ratio (Last Year: Sep22)=Total Current Assets/Total Current Liabilities
=23.49/9.312
=2.52255155

Better Therapeutics's current ratio of this year was 0.56770753. Better Therapeutics's current ratio of last year was 2.52255155. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Better Therapeutics's number of shares in issue this year was 38.495. Better Therapeutics's number of shares in issue last year was 23.693. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Better Therapeutics's gross margin of this year was . Better Therapeutics's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep22)
=0/28.221
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep21)
=0/57.798
=0

Better Therapeutics's asset turnover of this year was 0. Better Therapeutics's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Better Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Better Therapeutics  (OTCPK:BTTX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Better Therapeutics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Better Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.
Executives
Elder Granger director 5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman officer: Chief Medical Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe director, officer: See Remarks C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry director, 10 percent owner, officer: See Remarks 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino director C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust 10 percent owner C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen officer: See Remarks 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum director, 10 percent owner, officer: Chief Executive Officer 4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu director 311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski officer: Chief Commercial Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds officer: Chief Product Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona director 1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust 10 percent owner 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104

Better Therapeutics Headlines

From GuruFocus

Better Therapeutics to Participate in Two Upcoming Investor Conferences

By Business Wire Business Wire 02-09-2023